Aptus Capital Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Aptus Capital Advisors’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-95	Closed	-$5K	–	620
2021 Q2	$5K	Hold	95	–	–	﹤0.01%	527
2021 Q1	$5K	Hold	95	–	–	﹤0.01%	481
2020 Q4	$4K	Hold	95	–	–	﹤0.01%	444
2020 Q3	$4K	Hold	95	–	–	﹤0.01%	442
2020 Q2	$4K	Hold	95	–	–	﹤0.01%	391
2020 Q1	$3K	Hold	95	–	–	﹤0.01%	392
2019 Q4	$4K	Hold	95	–	–	﹤0.01%	480
2019 Q3	$3K	Buy	+95	New	+$3.53K	﹤0.01%	461

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Aptus Capital Advisors's XPH Position: Q3 2021 in Review

Aptus Capital Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2021, closing a stake of 95 shares — an estimated $5K sold.

Aptus Capital Advisors first reported a position in XPH in Q3 2019 and held it in 8 quarters. The position peaked at $5K in Q2 2021. 78 funds tracked by Wall St. Rank hold XPH as of Q3 2021.

Aptus Capital Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q3 2021 after selling out during the quarter.
Aptus Capital Advisors sold 95 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2021, an estimated $5K.
Aptus Capital Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q3 2019 and held it in 8 quarters.
Aptus Capital Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $5K in Q2 2021.
78 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2021.

Based on Aptus Capital Advisors's 13F filing for Q3 2021, filed 27 Oct 2021.